Oslo, 5 October 2022. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a
Norwegian immune-oncology company, today announces that an abstract has been
accepted for poster presentation at the Society for Immunotherapy of Cancer
(SITC) Annual Meeting 2022.

The abstract will be released on the SITC website 7 November 14:00 CEST. The
poster is scheduled for presentation during the SITC meeting 8-12th November
2022.

Poster Details:
Abstract Title: Molecular mechanisms of DC activation by melanoma cells
responding to LTX-315.
Presenter: Takahiro Yamazaki, Department of Radiation Oncology, Weill Cornell
Medical College, New York, USA

About SITC
The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference
Programs brings together stakeholders across the cancer immunotherapy field to
advance the science, discover breakthroughs and educate the world on cancer
immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual
meeting provides international leaders from academia, regulatory and government
agencies, as well as industry representatives with a multidisciplinary
educational and interactive environment focused on improving outcomes for all
cancer patients.

For more information, please contact: 
Ole Peter Nordby, ole.peter.nordby@lytixbiopharma.com

Lytix Biopharma in brief: 
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.